Amplia Therapeutics (ASX:ATX) Days Payable: 0.00 (As of Mar. 2026)

What is Amplia Therapeutics Days Payable?

Amplia Therapeutics ASX:ATX 36 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Amplia Therapeutics ranks worse than 141442.57% on this metric.

Amplia Therapeutics's average Accounts Payable for the six months ended in Mar. 2026 was A$1.26 Mil. Amplia Therapeutics's Cost of Goods Sold for the six months ended in Mar. 2026 was A$0.00 Mil.

The historical rank and industry rank for Amplia Therapeutics's Days Payable or its related term are showing as below:

ASX:ATX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Amplia Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

Amplia Therapeutics Days Payable Related Terms

Amplia Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Days Payable Chart

Amplia Therapeutics Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Days Payable

Get a 7-Day Free Trial

0.00

Amplia Therapeutics Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ASX:ATX vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Amplia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Days Payable falls into.

Save Embed

36GF Score

Amplia Therapeutics Ltd ASX:ATX

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amplia Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Amplia Therapeutics's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as

	Days Payable (A: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2025 )	+	Accounts Payable (A: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2026 )	*	Days in Period
=	( (1.564	+	1.4)	/	2 )	/	0	*	365
=	1.482					/	0	*	365
=	N/A

Amplia Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (1.116	+	1.4)	/	2 )	/	0	*	365 / 2
=	1.258					/	0	*	365 / 2
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Amplia Therapeutics (ASX:ATX) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amplia Therapeutics and its competitors. According to the industry distribution chart, Amplia Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.

Is Amplia Therapeutics' Days Payable too high?

Amplia Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Amplia Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.

How does Amplia Therapeutics' Days Payable compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Amplia Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amplia Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amplia Therapeutics stock overvalued right now?

Amplia Therapeutics (ASX:ATX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:CYP ASX:LTP ASX:BOT ASX:IMM ASX:PTX ASX:ENP ASX:ALA ASX:PAR ASX:NXN ASX:IMU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges INNMF:USA

Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000

Website https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).

36GF Score

Get the complete analysis for ASX:ATX

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14

Price

View ASX:ATX Analysis

See Days Payable data for all stocks →